NeuroVive Pharmaceutical AB – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “NeuroVive Pharmaceutical AB - Product Pipeline Review - 2012” provides data on the NeuroVive Pharmaceutical AB’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, NeuroVive Pharmaceutical AB’s corporate website, SEC filings, investor presentations and featured press releases, both from NeuroVive Pharmaceutical AB and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- NeuroVive Pharmaceutical AB - Brief NeuroVive Pharmaceutical AB overview including business description, key information and facts, and its locations and subsidiaries.

- Review of current pipeline of NeuroVive Pharmaceutical AB human therapeutic division.

- Overview of pipeline therapeutics across various therapy areas.

- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.

- Product profiles for late stage and clinical stage products of NeuroVive Pharmaceutical AB with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.

- Recent updates of the NeuroVive Pharmaceutical AB’s pipeline in the last quarter.

- Key discontinued and dormant projects.

- Latest news and deals relating to the products.

Reasons to buy

- Evaluate NeuroVive Pharmaceutical AB’s strategic position with total access to detailed information on its product pipeline.

- Assess the growth potential of NeuroVive Pharmaceutical AB in its therapy areas of focus.

- Identify new drug targets and therapeutic classes in the NeuroVive Pharmaceutical AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.

- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.

- Exploit collaboration and partnership opportunities with NeuroVive Pharmaceutical AB.

- Avoid Intellectual Property Rights related issues.

- Explore the dormant and discontinued projects of NeuroVive Pharmaceutical AB and identify potential opportunities in those areas.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

NeuroVive Pharmaceutical AB Snapshot 5

NeuroVive Pharmaceutical AB Overview 5

Key Information 5

Key Facts 5

NeuroVive Pharmaceutical AB – Research and Development Overview 6

Key Therapeutic Areas 6

NeuroVive Pharmaceutical AB – Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products – Monotherapy 9

NeuroVive Pharmaceutical AB – Pipeline Products Glance 10

NeuroVive Pharmaceutical AB – Late Stage Pipeline 10

Phase III Products/Combination Treatment Modalities 10

NeuroVive Pharmaceutical AB – Early Stage Pipeline Products 11

Pre-Clinical Products/Combination Treatment Modalities 11

Discovery Products/Combination Treatment Modalities 12

NeuroVive Pharmaceutical AB – Drug Profiles 13

CicloMulsion 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

NeuroSTAT 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

NVP014 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

NVP015 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

NVP016 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

NVP017 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

NVP018 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

NVP019 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

NeuroVive Pharmaceutical AB – Pipeline Analysis 24

NeuroVive Pharmaceutical AB – Pipeline Products by Therapeutic Class 24

NeuroVive Pharmaceutical AB – Pipeline Products By Target 25

NeuroVive Pharmaceutical AB – Pipeline Products by Route of Administration 26

NeuroVive Pharmaceutical AB – Pipeline Products By Mechanism of Action 27

NeuroVive Pharmaceutical AB – Recent Pipeline Updates 28

NeuroVive Pharmaceutical AB – Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

NeuroVive Pharmaceutical AB, Recent Developments 30

NeuroVive Pharmaceutical AB- Press Release 30

May 28, 2012: NeuroVive Reports Security Committee Approval To Proceed Phase III Study Of CicloMulsion 30

Jan 18, 2012: NeuroVive Pharma Enrolls 200 Patients In Phase III Study Of CicloMulsion 30

Financial Deals Landscape 32

NeuroVive Pharmaceutical AB, Deals Summary 32

NeuroVive Pharmaceutical AB, Pharmaceuticals & Healthcare, Deal Details 33

Asset Transactions 33

NeuroVive Acquires Patents To Neuro-STAT From CicloMulsion 33

Partnerships 34

Selcia Enters Into Research Agreement With NeuroVive Pharma 34

NeuroVive Pharma Enters Into Co-Development Agreement With to-BBB technologies 35

Equity Offering 37

NeuroVive Pharma Completes Rights Offering Of $5.42 Million 37

NeuroVive Completes IPO For $1.45 Million 39

Appendix 40

Methodology 40

Coverage 40

Secondary Research 40

Primary Research 40

Expert Panel Validation 40

Contact Us 41

Disclaimer 41

List of Tables

NeuroVive Pharmaceutical AB, Key Information 5

NeuroVive Pharmaceutical AB, Key Facts 5

NeuroVive Pharmaceutical AB – Pipeline by Indication, 2012 7

NeuroVive Pharmaceutical AB – Pipeline by Stage of Development, 2012 8

NeuroVive Pharmaceutical AB – Monotherapy Products in Pipeline, 2012 9

NeuroVive Pharmaceutical AB – Phase III, 2012 10

NeuroVive Pharmaceutical AB – Pre-Clinical, 2012 11

NeuroVive Pharmaceutical AB – Discovery, 2012 12

NeuroVive Pharmaceutical AB – Pipeline By Therapeutic Class, 2012 24

NeuroVive Pharmaceutical AB - Pipeline By Target, 2012 25

NeuroVive Pharmaceutical AB – Pipeline By Route of Administration, 2012 26

NeuroVive Pharmaceutical AB – Pipeline Products By Mechanism of Action, 2012 27

NeuroVive Pharmaceutical AB – Recent Pipeline Updates, 2012 28

NeuroVive Pharmaceutical AB, Other Locations 29

NeuroVive Pharmaceutical AB, Subsidiaries 29

NeuroVive Pharmaceutical AB, Deals Summary 32

NeuroVive Acquires Patents To Neuro-STAT From CicloMulsion 33

Selcia Enters Into Research Agreement With NeuroVive Pharma 34

NeuroVive Pharma Enters Into Co-Development Agreement With to-BBB technologies 35

NeuroVive Pharma Completes Rights Offering Of $5.42 Million 37

NeuroVive Completes IPO For $1.45 Million 39

List of Figures

NeuroVive Pharmaceutical AB – Pipeline by Indication, 2012 7

NeuroVive Pharmaceutical AB – Pipeline by Stage of Development, 2012 8

NeuroVive Pharmaceutical AB – Monotherapy Products in Pipeline, 2012 9

NeuroVive Pharmaceutical AB – Pipeline By Therapeutic Class, 2012 24

NeuroVive Pharmaceutical AB - Pipeline Products By Mechanism of Action, 2012 27